Literature DB >> 19724286

Anomalous venous blood flow and iron deposition in multiple sclerosis.

Ajay Vikram Singh1, Paolo Zamboni.   

Abstract

Multiple sclerosis (MS) is primarily an autoimmune disorder of unknown origin. This review focuses iron overload and oxidative stress as surrounding cause that leads to immunomodulation in chronic MS. Iron overload has been demonstrated in MS lesions, as a feature common with other neurodegenerative disorders. However, the recent description of chronic cerebrospinal venous insufficiency (CCSVI) associated to MS, with significant anomalies in cerebral venous outflow hemodynamics, permit to propose a parallel with chronic venous disorders (CVDs) in the mechanism of iron deposition. Abnormal cerebral venous reflux is peculiar to MS, and was not found in a miscellaneous of patients affected by other neurodegenerative disorders characterized by iron stores, such as Parkinson's, Alzheimer's, amyotrophic lateral sclerosis. Several recently published studies support the hypothesis that MS progresses along the venous vasculature. The peculiarity of CCSVI-related cerebral venous blood flow disturbances, together with the histology of the perivenous spaces and recent findings from advanced magnetic resonance imaging techniques, support the hypothesis that iron deposits in MS are a consequence of altered cerebral venous return and chronic insufficient venous drainage.

Entities:  

Mesh:

Year:  2009        PMID: 19724286     DOI: 10.1038/jcbfm.2009.180

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  58 in total

1.  Alternative therapies: Desperate measures.

Authors:  Jennifer Berglund
Journal:  Nature       Date:  2012-04-12       Impact factor: 49.962

2.  Chronic cerebrospinal venous insufficiency in multiple sclerosis: a historical perspective.

Authors:  Michael D Dake; Robert Zivadinov; E Mark Haacke
Journal:  Funct Neurol       Date:  2011 Oct-Dec

3.  Custom CGH array profiling of copy number variations (CNVs) on chromosome 6p21.32 (HLA locus) in patients with venous malformations associated with multiple sclerosis.

Authors:  Alessandra Ferlini; Matteo Bovolenta; Marcella Neri; Francesca Gualandi; Alessandra Balboni; Anton Yuryev; Fabrizio Salvi; Donato Gemmati; Alberto Liboni; Paolo Zamboni
Journal:  BMC Med Genet       Date:  2010-04-28       Impact factor: 2.103

4.  ["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients].

Authors:  C Krogias; A Schröder; H Wiendl; R Hohlfeld; R Gold
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

Review 5.  Pathogenic implications of iron accumulation in multiple sclerosis.

Authors:  Rachel Williams; Cassandra L Buchheit; Nancy E J Berman; Steven M LeVine
Journal:  J Neurochem       Date:  2011-11-11       Impact factor: 5.372

Review 6.  CCSVI and MS: no meaning, no fact.

Authors:  Claudio Baracchini; Matteo Atzori; Paolo Gallo
Journal:  Neurol Sci       Date:  2012-05-09       Impact factor: 3.307

7.  Cerebral venous hemodynamic abnormalities in episodic and chronic migraine.

Authors:  B Petolicchio; A Viganò; Lazzaro di Biase; D Tatulli; M Toscano; E Vicenzini; F Passarelli; V Di Piero
Journal:  Funct Neurol       Date:  2016 Apr-Jun

8.  Vascular intervention for multiple sclerosis.

Authors:  Michael Kolber; Ken Makus; G Michael Allan; Noah Ivers
Journal:  Can Fam Physician       Date:  2011-06       Impact factor: 3.275

9.  Multiple sclerosis and chronic cerebrospinal venous insufficiency: the neuroimaging perspective.

Authors:  M Filippi; M A Rocca; F Barkhof; R Bakshi; F Fazekas; O Khan; D Pelletier; A Rovira; J Simon
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-03       Impact factor: 3.825

10.  Impaired Postnatal Myelination in a Conditional Knockout Mouse for the Ferritin Heavy Chain in Oligodendroglial Cells.

Authors:  Rensheng Wan; Veronica T Cheli; Diara A Santiago-González; Shaina L Rosenblum; Qiuchen Wan; Pablo M Paez
Journal:  J Neurosci       Date:  2020-08-31       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.